IONS vs SRPT โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
SRPT Captures Institutional Edge (3โ1 Pillars ยท 6โ4 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Sarepta Therapeutics,, Inc. Common Stock (SRPT) driven by superior Valuation, Growth & Margin, Momentum & Technical while IONS counters with relative strength in Options & Structure. Fundamentally, IONS trades at 90.9x Forward P/E with -58.8% operating margin (+54.9% YoY revenue) versus SRPT at 10.8x Forward P/E and -0.4% operating margin (-4.5% YoY). In options structure, IONS sits in BREAKDOWN (17th %ile IV; Dealer Gamma Walls on Pro) against SRPT sits in BREAKDOWN (7th %ile IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | IONS Revenue | SRPT Revenue | IONS Op. Margin | SRPT Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| FY2018 | $600M | $300M | -10.2% | -114.1% | IONS |
| FY2019 | $1.12B | $380M | 32.6% | -185.3% | IONS |
| FY2020 | $730M | $460M | -23.6% | -123.8% | IONS |
| FY2021 | $810M | $610M | -3.7% | -75.1% | IONS |
| FY2022 | $590M | $840M | -69.8% | -63.5% | SRPT |
| FY2023 | $790M | $1.14B | -44.9% | -23.4% | SRPT |
| FY2024 | $710M | $1.79B | -67.4% | 12.2% | SRPT |
| FY2025 | $940M | $1.86B | -40.4% | -37.5% | SRPT |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | IONS | SRPT | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $4.7B | $1.7B | Larger Scale | IONS |
| Trailing P/E Ratio Valuation | 90.9x | N/M | Lower Multiple | IONS |
| Forward P/E Ratio Valuation | 90.9x | 10.8x | Lower Multiple | SRPT |
| Revenue Growth (YoY) Growth | +54.9% | -4.5% | Higher Growth | IONS |
| Operating Margin (TTM) Profitability | -58.8% | -0.4% | Higher Margin | SRPT |
| Net Profit Margin Profitability | -56.9% | -5.9% | Higher Margin | SRPT |
| Return on Equity (ROE) Capital Efficiency | -108.0% | -8.1% | Higher ROE | SRPT |
| 52-Week Range Position Momentum | 2% ($27โ$87) | 5% ($15โ$25) | Stronger Trend | SRPT |
| Beta / 30D Volatility Risk Regime | 0.18ฮฒ ยท 86% Vol | 1.47ฮฒ ยท 58% Vol | Lower Realized Risk | SRPT |
| Unified Institutional Score Composite Signal | 63.9 / 100 (BUY) | 37.8 / 100 (SELL) | Higher Composite | IONS |